TFS Capital’s Blueprint Medicines BPMC Stock Holding History

TFS Capital’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-17,478	Closed	-$354K	–	759
2016 Q2	$354K	Buy	+17,478	New	+$318K	0.07%	534

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

TFS Capital's BPMC Position: Q3 2016 in Review

TFS Capital sold out of Blueprint Medicines (BPMC) in Q3 2016, closing a stake of 17,478 shares — an estimated $354K sold.

TFS Capital first reported a position in BPMC in Q2 2016 and held it in 1 quarter. The position peaked at $354K in Q2 2016. 87 funds tracked by Wall St. Rank hold BPMC as of Q3 2016.

TFS Capital reported no remaining Blueprint Medicines position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 17,478 Blueprint Medicines shares in Q3 2016, an estimated $354K.
TFS Capital first reported a position in Blueprint Medicines in Q2 2016 and held it in 1 quarter.
TFS Capital's Blueprint Medicines position peaked at $354K in Q2 2016.
87 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.